
COVID mRNAã¯ã¯ãã³æ¥çš®åŸãããæ»äº¡çãææã«å¢å ããããšãæ¥æ¬äººç ç©¶è ãçºèŠ
å èšäºã¯ãã¡ããã/Click here to read the original article.
æ¥æ¬ã®æ»èªä»ãç ç©¶ã§ãç¹ã«3åç®ã®COVID-19 mRNAã¯ã¯ãã³æ¥çš®åŸã«ãããæ»äº¡çãçµ±èšçã«ææã«å¢å ããããšã倿ããããžã§ã³ã»ãã£ã³ãã«å士ã¯èªèº«ã®ããããã£ã¹ãã§ãã®ç ç©¶ãåæãããå¥ã®ãšããœãŒãã§ããã£ã³ãã«ã¯ãã³ãã³å€§åŠã»ã³ããžã§ãŒãžãºã®è «çåŠææã¢ã³ã¬ã¹ã»ãã«ã°ãªãŒã·ã¥ãšãã®ç ç©¶ã«ã€ããŠè°è«ããã
èåãªå»çã³ã¡ã³ããŒã¿ãŒã§ãããžã§ã³ã»ãã£ã³ãã«å士ã«ããã°ãæ¥æ¬ã®æ»èªä»ãç ç©¶ã§ãç¹ã«3åç®ã®COVID-19 mRNAã¯ã¯ãã³æ¥çš®åŸã«ãããæ»äº¡çãçµ±èšçã«ææã«å¢å ããããšã倿ããã
4æ13æ¥ã®ããããã£ã¹ãã§ããã£ã³ãã«æ°ã¯4æ8æ¥ã«Cureusèªã«çºè¡šãããç ç©¶ã«ã€ããŠè¿°ã¹ãããã®ç ç©¶ã¯ãæ¥æ¬æ¿åºã®å ¬åŒçµ±èšãåæããCOVID-19ãã³ãããã¯ïŒ2020-2022å¹ŽïŒæã®å¹Žéœ¢èª¿æŽããæ»äº¡çãšãã³ãããã¯åã®æ»äº¡çãæ¯èŒãããã®ã§ããã
ãã£ã³ãã«æ°ã¯ãŸããæ¬æ¥æŸéãããããããã£ã¹ãã§ãè «çåŠè ã¢ã³ã¬ã¹ã»ãã«ã°ãªãŒã·ã¥æ°ãšãã®ç ç©¶çµæã«ã€ããŠè°è«ããã
ãã£ã³ãã«æ°ã¯ãŸãã2021幎ããçŸåšãŸã§ã®æ¥æ¬ã«ãããå šæ»å ã«ããæ»äº¡çã®å¢å ã瀺ããã2021å¹Žã®æ»äº¡çã¯2.1ïŒ å¢å ãã2022幎ã«ã¯9.6ïŒ å¢å ããããšã瀺ãããã
ããã«é¢ããŠã¯ã2020幎ã«ã¯ææãªéå°æ»äº¡çã¯èŠãããªãã£ããã1åç®ãš2åç®ã®ã¯ã¯ãã³æ¥çš®åŸã®2021幎ã«ã¯1.1ïŒ å¢å ãã人å£ã®3åã®2ã3åç®ã®mRNA COVID-19ã¯ã¯ãã³ãæ¥çš®ããåŸã®2022幎ã«ã¯2.1ïŒ å¢å ããã
ç ç©¶ã«ãããšãããã€ãã®çã®æ»äº¡çã¯9.7ïŒ ãå¢å ããã

ããŒã¿ã¯ã以äžã®ããã«ããæ»äº¡çã®ææãªå¢å ã瀺ããïŒ
åµå·£ããïŒ2020幎ã«2.5ïŒ å¢å ã2021幎ã«7.6ïŒ å¢å ã2022幎ã«9.7ïŒ å¢å ã
çœè¡ç ïŒ2020幎ã«0.2ïŒ ã®æžå°ã2021幎ã«1.7ïŒ ã2022幎ã«8.0ïŒ ã®å¢å ã
åç«è ºããïŒ2020幎ã«1.2ïŒ å¢å ã2021幎ã«5.3ïŒ å¢å ã2022幎ã«5.9ïŒ å¢å ã
å£è ããããã³åœé ããïŒ2020幎ã«0.6ïŒ ã®æžå°ã2021幎ã«1.3ïŒ ã2022幎ã«5.5ïŒ ã®å¢å ã
ç®èããïŒ2020幎ã«0.6ïŒ å¢å ã2021幎ã«0.1ïŒ å¢å ã2022幎ã«3.2ïŒ å¢å ã
åå®®ããïŒ2020幎ã«1.1%ã2021幎ã«1.3%ã®æžå°ã2022幎ã«2.5%ã®å¢å

ãã£ã³ãã«ã¯ããã®ãããªçžé¢é¢ä¿ã ãå¥åŠãªå¶ç¶ã®äžèŽ ããšåŒãã§ããã
ããã¹ãŠã®çæ»äº¡ã¯çµ±èšçã«ææã§ããããšãã£ã³ãã«ã¯èšãããéå°æ»äº¡ã¯2021幎ã«åºçŸãã2022幎ã«ã¯ããã«å¢å ãããããã«ãææãªéå°æ»äº¡çã¯2021幎8æä»¥éã«èгå¯ãããããäžæ¹ãäžè¬äœæ°ãžã®éå£äºé²æ¥çš®ã¯2021幎4æé ã«éå§ããããã
ãã£ã³ãã«æ°ã¯ããã®ç ç©¶ã§ã¯æ°ããªçäŸã¯æž¬å®ãããŠããããçã®çš®é¡ã«ãã£ãŠã¯çºçã«äœå¹Žãããããã®ããããããã®èª¿æ»çµæã¯ã¯ã¯ãã³ãæ¢åã®è «çãæã€æ£è ã®çæ»äº¡ãå éãããŠããå¯èœæ§ã瀺åããŠãããšææããã
ããã«ã¯äœããªããé»ã
èåãªè «çåŠè ã§ããããã³ãã³å€§åŠã»ã³ãã»ãžã§ãŒãžææã®ãã«ã°ãªãã·ã¥ã¯ããã³ãããã¯ã®åæããRNAããŒã¹ã®ã¯ã¯ãã³ã®æœåšçãªã¹ã¯ã«ã€ããŠèŠåããŠããã
2022幎ã圌ã¯BMJèªã«çœè¡ç ãéããžãã³ãªã³ãè «ããã®ä»mRNA泚å°ã«é¢é£ããçã«ã€ããŠèŠåããç·æ¥æžç°¡ãéã£ãã
仿¥çºè¡šããããã£ã³ãã«ãšã®å¥ã®ã€ã³ã¿ãã¥ãŒã®äžã§ããã«ã°ãªãã·ã¥ã¯ãããŒã¹ã¿ãŒæäžãåããæ£è ã§æ¥éã«é²è¡ããçã®æ°ã«ãªããã¿ãŒã³ã芳å¯ãããšè¿°ã¹ãã
ãã«ã°ãªãã·ã¥ã¯ãã£ã³ãã«ã«ãäœå¹Žãå®å®ããŠããã¡ã©ããŒãæ£è ãçªç¶ãæ¥éã«åçºããããšã話ããã
ç§ã¯å«ãã ããé±å±±ã®ã«ããªã¢ã ïŒããšããšãã«ã°ãªãã·ã¥ã¯èšã£ããããçŽç²ãªéžè©±ã§ãããããã«ã¯äœããªããã
ã¯ã¯ãã³ã®ç ç©¶ãè¡ã£ãŠãããã«ã°ãªãã·ã¥ã¯ããä»ã§ã¯æ Œèšã«ãªã£ãŠãã ããšèšã£ãããäºé²ããããšããç æ°ããå®éã«ãã®ã¯ã¯ãã³ã«ãã£ãŠåŒãèµ·ããããã»ã©ãå ç«ç³»ãæ··ä¹±ããã ããŸã§ããã®åŸã®ããŒã¹ã¿ãŒæäžã¯ãŸããŸã广ããªããªãã®ã ãšã
ãã«ã°ãªãã·ã¥ã¯ãèªåã®èгå¯ãæããããšããã«ããããããã"ãã¡ãã¡ãã "å»åž«ããé£çµ¡ãåãããšããã
ã¯ã¯ãã³ãçãä¿é²ããå¯èœæ§
æ¥æ¬ã®ç ç©¶èè ãšãã«ã°ãªãŒã·ã¥æ°ã¯ãmRNAã¯ã¯ãã³ãçã®çºçãšé²è¡ãä¿é²ããå¯èœæ§ã®ããããã€ãã®ã¡ã«ããºã ã«ã€ããŠè°è«ããã
ããããã®ã¹ãã€ã¯ã¿ã³ãã¯è³ªãšããç²åã¯åŸ®å°è¡æ ãèªçºããŸããã
ãç§ã®ãã¬ãŒãã³ã°ã§ã¯ãåç«è ºçãšèµèçãè¡æ¶²ååºã®äº¢é²ãšé¢é£ããŠããããšãç¹ã«èŠããŠããŸããã
ãããæ£è ã«ãããæ»äº¡ã®äž»ãªåå ã®äžã€ã¯ãããã«é¢é£ããè¡æ çïŒè¡ã®å¡ïŒã§ãããšãç ç©¶èè ãã¯ææããã
è¡æ¶²ååºã®ãªã¹ã¯ã«å ããŠããã®ç ç©¶ã§ã¯ãã¯ã¯ãã³ãèªç¶å ç«åå¿ãé»å®³ããããšã«ãã£ãŠçã®å ç«ç£èŠãæå¶ããå¯èœæ§ã匷調ãããã
ããã¡ãããçã¯å®æçã«çºçããŸãããå ç«ç³»ããããåŠçããŸããã
ãT现èå¿çã¯ã3åç®ã®æ³šå°ãæåã®ããŒã¹ã¿ãŒã®åŸãæå¶ãããããç²åŒããŸãããšãã«ã°ãªãŒã·ã¥ã¯èšã£ãããç§ã®èšºçæã§ããå€ãä¹ãåãããã«æ¥ã®ããŒã¹ã¿ãŒæ³šå°ãåããããå§ããŠããŸããä¿¡ããããªãããšã ãã
ãSARS-CoV-2ã®mRNA-LNPïŒè質ããç²åïŒã¯ã¯ãã³æ¥çš®åŸãçã®å ç«ç£èŠã«éèŠãªåœ¹å²ãæããIåã€ã³ã¿ãŒãã§ãã³å¿çãæå¶ãããããšã瀺ããç ç©¶ããããã
ãã£ã³ãã«ãšãã«ã°ãªãŒã·ã¥ã¯ãŸããã¯ã¯ãã³ãDNAæå·ãçªç¶å€ç°ãçŽæ¥åŒãèµ·ãããç¹ã«P53ãBRCAïŒä¹³ããéºäŒåïŒãMSH3ã®ãããªããæå¶éºäŒåãé»å®³ããããšã«ãã£ãŠãããã«ã€ãªããå¯èœæ§ã«ã€ããŠãè°è«ããã
ç ç©¶èè ãã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã«ããACE2å容äœã®ããŠã³ã¬ã®ã¥ã¬ãŒã·ã§ã³ããDNAãå·ã€ãçãåŒãèµ·ããå¯èœæ§ã®ããéå°ãªé žåã¹ãã¬ã¹ãããããå¯èœæ§ã瀺åããã
ãŸãããã®mRNAãããã²ãã ã«é転åãããæ ¢æ§ççãDNAæå·ããããªã¹ã¯äžæãåŒãèµ·ããå¯èœæ§ãããããšã瀺ãç ç©¶ãåŒçšããã
æåŸã«ãç ç©¶èè ãã¯ãã¹ãã€ã¯ã¿ã³ãã¯è³ªã®çµåèœåã«ãããmRNAã¯ã¯ãã³ããšã¹ããã²ã³å容äœÎ±ïŒERαïŒã«ç¹ç°çã«çµåããè»¢åæŽ»æ§ãã¢ããã¬ã®ã¥ã¬ãŒãããããšã§ãä¹³ãããåµå·£ãããåç«è ºããã«ã€ãªããããšãææ¡ããã
ãã«ã°ãªãã·ã¥ã¯ãŸãã"è¬åå±ã®å£ãã "èãããšããè¡ç®¡å ååº-"äž»èŠãªè¡ç®¡ã«ã§ããéåžžã«é·ãè¡æ "-ã®åé¡ãæèµ·ããã
ãã£ã³ãã«ã¯ãè±åœãæ ç¹ãšããè¬åå±ãšè©±ãããšããã圌ããé²è åŠçãããŠããéºäœã®çŽ20ïŒ ã«èŠããããšã®ããšã§ãã£ããããããã®è¡æ ãã¢ããã€ãã»ã¿ã³ãã¯è³ªã§ã§ããŠããããšã¯ã»ãŒç¢ºå®ã§ãããã
ãç§ã®å¿é ã¯ããŸã äœãèŠããŠããªãã®ã§ã¯ãªãããšããããšã§ããç§ãã¡ã¯å€§è¥¿æŽã暪æãããšãã«æ°·å±±ãããã€ãèŠãŠããã ãã§ã倧ããªæ°·åºã¯ãŸã æ¥ãŠããªããã
圌ããç§ãã¡ã«åãã€ããããšã¯æããã
ãã£ã³ãã«æ°ãšãã«ã°ãªãã·ã¥æ°ã¯ãä»åœã®ä¿å¥æ©é¢ãæ¿åºã«ãã£ãŠåæ§ã®ããæ»äº¡çããŒã¿ãå ¬ã«å ±æãããŠããªãããšãåé¡ã§ãããšåŒ·èª¿ããã
ããªããããã®ããŒã¿ãç±³åœãè±åœã®è«æã§çºè¡šãããªãã®ããããã¯æªè§£æ±ºã®åé¡ã§ãããšãã£ã³ãã«æ°ã¯è¿°ã¹ãä»ã®ç ç©¶ãšã¯ç°ãªããæ¥æ¬ã®ç ç©¶è 㯠ãCOVID-19ææãã®ãã®ãããã¯ããŠã³ã«ããããæ²»çã®æžå° ããéé£ããŠããªããšææããã
ãã«ã°ãªãã·ã¥æ°ã¯ãå°éå®¶ãåœå±ã®é¢äžãšéææ§ã®æ¬ åŠãæ¹å€ããã¯ã¯ãã³ã®æœåšçãªã¹ã¯ã«é¢ããæ å ±ãæå§ããŠãããšéé£ããã
ãã«ã°ãªãŒã·ã¥ã¯ãã圌ããç§ãã¡ã«åãã€ããŠããããšã¯æããã§ãããšèšããªãããã人ã ã¯çªç¶ç®ãèŠãŸããã®ã§ããéšããã人ãã¡ã¯ããéšããããä¿¡ããããªãã£ãããšèªããŠããŸãã
ãã£ã³ãã«ãåæèŠã§ãããããã人ã ã¯ãã°ãã°å ·äœçãªç¥èãäžè¶³ããŠãããç§ããã®éšé¡ã«å ¥ããç§ãã¡ãæ¬åœã«åºã®ãããªéãããŸãã£ãŠããããšã«æ°ã¥ããŸã§ãé·ãæéãããã£ãã
ãã£ã³ãã«ãšãã«ã°ãªãŒã·ã¥ã¯ãæ¥æ¬ã®ç ç©¶çµæãèžãŸããŠãããåºç¯ãªèª¿æ»ãšããããŒã¿ã®é瀺ãåŒã³ãããmRNAã¯ã¯ãã³ãšããæ»äº¡å¢å ã®æœåšçé¢é£æ§ã«ã€ããŠã®ç§åŠç調æ»ãšäžè¬åžæ°ã®èªèãç·æ¥ã«å¿ èŠã§ããããšã匷調ããã
ãã£ã³ãã«ã®ãæ¥æ¬ããŒã¿ã4æ13æ¥ããããã£ã¹ããã芧ãã ããïŒ
ãã£ã³ãã«ãšãã«ã°ãªãŒã·ã¥ã®ãã³ããã¯ã¯ãã³æ¥çš®åŸã®çã4æ15æ¥ããããã£ã¹ããã芧ãã ããïŒ